AVR 5.71% $13.20 anteris technologies ltd

Interim vax results due?, page-16

  1. 6,439 Posts.
    lightbulb Created with Sketch. 42
    Any company that says this you know they have found something and I assume it would be good, if not it would of been cut very quick smart.

    ADMEDUS HSV-2 STUDY TO CONTINUE AFTER POSITIVE INTERIM INDEPENDENT REVIEW
    Safety Review Committee unanimously agrees study should continue
     No safety issues seen in the study to date
     Admedus increases stake in Admedus Vaccines to 72%
     More than 80% of study participants have entered the study Brisbane,
    Australia 27th August, 2015
    Admedus Limited (ASX:AHZ) announced today that an independent Safety Review Committee (SRC) has examined initial safety data from the first group of subjects dosed in its Herpes Simplex 2 (HSV-2) vaccine Phase II study and unanimously recommended that the trial continue without any modifications to the study
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
(20min delay)
Last
$13.20
Change
-0.800(5.71%)
Mkt cap ! $279.0M
Open High Low Value Volume
$14.00 $14.00 $13.11 $947.2K 71.30K

Buyers (Bids)

No. Vol. Price($)
1 500 $13.10
 

Sellers (Offers)

Price($) Vol. No.
$13.35 300 1
View Market Depth
Last trade - 16.10pm 30/08/2024 (20 minute delay) ?
AVR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.